Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart
Open Access
- 17 June 2020
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 288 (5) , 491-506
Abstract
As the heart matures during embryogenesis from its foetal stages, several structural and functional modifications take place to form the adult heart. This process of maturation is in large part due to an increased volume and work load of the heart to maintain proper circulation throughout the growing body. In recent years, it has been observed that these changes are reversed to some extent as a result of cardiac disease. The process by which this occurs has been characterized as cardiac foetal reprogramming and is defined as the suppression of adult and re‐activation of a foetal genes profile in the diseased myocardium. The reasons as to why this process occurs in the diseased myocardium are unknown; however, it has been suggested to be an adaptive process to counteract deleterious events taking place during cardiac remodelling. Although still in its infancy, several studies have demonstrated that targeting foetal reprogramming in heart failure can lead to substantial improvement in cardiac functionality. This is highlighted by a recent study which found that by modulating the expression of 5‐oxoprolinase (OPLAH, a novel cardiac foetal gene), cardiac function can be significantly improved in mice exposed to cardiac injury. Additionally, the utilization of angiotensin receptor neprilysin inhibitors (ARNI) has demonstrated clear benefits, providing important clinical proof that drugs that increase natriuretic peptide levels (part of the foetal gene programme) indeed improve heart failure outcomes. In this review, we will highlight the most important aspects of cardiac foetal reprogramming and will discuss whether this process is a cause or consequence of heart failure. Based on this, we will also explain how a deeper understanding of this process may result in the development of novel therapeutic strategies in heart failure.Keywords
This publication has 146 references indexed in Scilit:
- Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of CardiomyocytesCirculation Research, 2013
- AC-NP: A Novel Chimeric Peptide with Natriuretic and Vasorelaxing ActionsPLOS ONE, 2011
- Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditureThe American Journal of Clinical Nutrition, 2010
- Do engineered natriuretic peptides have greater therapeutic potential than do native peptides?Cardiovascular Research, 2010
- Energy Metabolic Phenotype of the Cardiomyocyte During Development, Differentiation, and Postnatal MaturationJournal of Cardiovascular Pharmacology, 2010
- Return to the fetal gene programAnnals of the New York Academy of Sciences, 2010
- Cardiomyocyte enlargement, proliferation and maturation during chronic fetal anaemia in sheepExperimental Physiology, 2009
- Transcription profiling of HCN-channel isotypes throughout mouse cardiac developmentBasic Research in Cardiology, 2009
- Remodelling of gap junctions and connexin expression in diseased myocardiumCardiovascular Research, 2008
- Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteinsJournal of Molecular and Cellular Cardiology, 2007